1. Search Result
Search Result
Results for "

lanosterol

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

10

Natural
Products

2

Recombinant Proteins

8

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17514
    Itraconazole
    20+ Cited Publications

    R51211

    Fungal Hedgehog Cytochrome P450 Autophagy Antibiotic Bacterial Infection Cancer
    Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor .
    Itraconazole
  • HY-76200
    Voriconazole
    10+ Cited Publications

    UK-109496

    Fungal Bacterial Infection Neurological Disease Cancer
    Voriconazole (UK-109496) is a second-generation, broad-spectrum triazole antifungal agent that inhibits fungal ergosterol biosynthesis. Voriconazole exerts its antifungal activity by inhibition of 14-α-lanosterol demethylation, which is mediated by fungal cytochrome P450 enzymes. Voriconazole can penetrate the blood brain barrier (BBB) .
    Voriconazole
  • HY-W020033
    Lanosterol
    3 Publications Verification

    Endogenous Metabolite Neurological Disease
    Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases .
    Lanosterol
  • HY-160972

    LXR Neurological Disease Cancer
    MM0299 is a selective lanosterol synthase (LSS) inhibitor with an IC50 value of 2.22 μM. MM0299 depletes intracellular cholesterol and acts as a growth inhibitor for glioma stem-like cells. MM0299 exhibits anti-glioblastoma activity. MM0299 is applicable to research related to glioblastoma .
    MM0299
  • HY-17514S

    R51211-d5

    Fungal Hedgehog Cytochrome P450 Autophagy Antibiotic Infection Cancer
    Itraconazole-d5 is the deuterium labeled Itraconazole. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects .
    Itraconazole-d5
  • HY-B0293A
    Butoconazole
    2 Publications Verification

    Fungal Infection
    Butoconazole, an imidazole antifungal agent, is active against Candida spp. and effective against vaginal infections due to Candida albicans. Butoconazole is presumed to function as other imidazole derivatives via inhibition of steroid synthesis .
    Butoconazole
  • HY-B2012

    DPX-H6573

    Environmental Pollutants Fungal Infection
    Flusilazole (DPX-H6573) is a broad-spectrum fungicide and cytochrome P-450 inhibitor that can be used in studies related to fungal infections .
    Flusilazole
  • HY-76200S
    Voriconazole-d3
    2 Publications Verification

    UK-109496-d3

    Fungal Infection
    Voriconazole-d3 is the deuterium labeled Voriconazole. Voriconazole (UK-109496) is a second-generation, broad-spectrum triazole antifungal agent that inhibits fungal ergosterol biosynthesis. Voriconazole exerts its antifungal activity by inhibition of 14-α-lanosterol demethylation, which is mediated by fungal cytochrome P450 enzymes .
    Voriconazole-d3
  • HY-17514S1

    R51211-d3

    Antibiotic Autophagy Bacterial Cytochrome P450 Fungal Hedgehog Infection Cancer
    Itraconazole-d3 (R51211-d3) is the deuterium labeled Itraconazole (HY-17514) . Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor.
    Itraconazole-d3
  • HY-17514R

    R51211 (Standard)

    Reference Standards Fungal Hedgehog Cytochrome P450 Autophagy Antibiotic Bacterial Infection Cancer
    Itraconazole (Standard) is the analytical standard of Itraconazole. This product is intended for research and analytical applications. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor .
    Itraconazole (Standard)
  • HY-W020033R

    Reference Standards Endogenous Metabolite Neurological Disease
    Lanosterol (Standard) is the analytical standard of Lanosterol. This product is intended for research and analytical applications. Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases[1][2].
    Lanosterol (Standard)
  • HY-76200R

    UK-109496 (Standard)

    Reference Standards Fungal Bacterial Infection Cancer
    Voriconazole (Standard) is the analytical standard of Voriconazole. This product is intended for research and analytical applications. Voriconazole (UK-109496) is a second-generation, broad-spectrum triazole antifungal agent that inhibits fungal ergosterol biosynthesis. Voriconazole exerts its antifungal activity by inhibition of 14-α-lanosterol demethylation, which is mediated by fungal cytochrome P450 enzymes .
    Voriconazole (Standard)
  • HY-W020033S

    Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease
    Lanosterol-d6 is deuterium labeled Lanosterol. Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol s
    Lanosterol-d6
  • HY-W1127089

    Fungal Cytochrome P450 Interleukin Related Infection Inflammation/Immunology
    Antifungal agent 136 (Compound M-15) is an irreversible fungal lanosterol 14α-demethylase (CYP51) inhibitor. Antifungal agent 136 exhibits potent antifungal activity against drug-resistant Candida albicans and downregulates IL-6 expression. Antifungal agent 136 is promising for research of fungal infection and inflammatory disease .
    Antifungal agent 136
  • HY-17514S2

    R51211-d9

    Fungal Hedgehog Bacterial Autophagy Cytochrome P450 Antibiotic Infection
    Itraconazole-d9 is the deuterium labeled Itraconazole . Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor .
    Itraconazole-d9
  • HY-W706180

    Isotope-Labeled Compounds Fungal Infection
    (±)-Triadimefon-d4 is deuterium labeled Triadimefon. Triadimefon is a triazole fungicide used to control powdery mildew, rusts, and other fungal pests on grains, fruit and vegetable crops, turf, shrubs, and trees. Triadimefon inhibits lanosterol 14α-demethylase, interfering with oxidative demethylation reactions in the ergosterol biosynthesis pathway of fungi, and also blocks gibberellin biosynthesis .
    (±)-Triadimefon-d4
  • HY-W743862

    Demethyldihydrolanosterol

    Biochemical Assay Reagents Metabolic Disease
    Demethyldihydrolanosterol belongs to the class of sterols and is a derivative of lanosterol. Demethyldihydrolanosterol can be studied in research on cholesterol biosynthesis and the development of pharmaceuticals targeting cholesterol-related pathways.
    Dihydro T-MAS
  • HY-76200B

    UK-109496 camphorsulfonate

    Fungal Bacterial Infection Cancer
    Voriconazole (UK-109496) camphorsulfonate is a second-generation, broad-spectrum triazole antifungal agent that inhibits fungal ergosterol biosynthesis. Voriconazole camphorsulfonate exerts its antifungal activity by inhibition of 14-α-lanosterol demethylation, which is mediated by fungal cytochrome P450 enzymes .
    Voriconazole camphorsulfonate
  • HY-105191

    RS-21607

    Cytochrome P450 Reactive Oxygen Species (ROS) Metabolic Disease
    Azalanstat (RS-21607) is an inhibitor of heme oxygenase and lanosterol 14α-demethylase, with inhibitory activity against HO-1 (IC50 = 5.5 µM) and HO-2 (IC50 = 24.5 µM). Azalanstat reduces the maturation rate of rat oocytes, increases rat oocyte degeneration, and partially inhibits progesterone production in preovulatory follicles of rats .
    Azalanstat
  • HY-W264454

    Bacterial Infection
    Antibacterial agent 303 (compound 3) is an antibacterial agent exhibiting potent antibacterial activity against MDR strains, with MICs of 10 and 100 µg/mL against Pseudomonas aeruginosa MDR1 and Staphylococcus aureus MDR strains, respectively. Antibacterial agent 303 displays strong binding affinities to E. coli DNA gyrase and Candida albicans lanosterol 14α-demethylase. Antibacterial agent 303 can be used for drug-resistant infections research .
    Antibacterial agent 303
  • HY-117219

    Cytochrome P450 HMG-CoA Reductase (HMGCR) Endogenous Metabolite Metabolic Disease
    SKF 104976 is a 3,2-carboxylic acid derivative with potent 14-alpha-demethylase (14 alpha DM) inhibitory activity. SKF 104976 inhibited 14 alpha DM activity by 50% at 2 nM in Hep G2 cell extracts. SKF 104976 inhibited the incorporation of [14C]acetate into cholesterol in intact cells at similar concentrations, accompanied by accumulation of lanosterol, and resulted in a 40-70% decrease in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) activity. SKF 104976 did not affect the uptake and degradation of low-density lipoprotein in Hep G2 cells, indicating that HMGR and low-density lipoprotein receptor activities are not coordinately regulated under these conditions. The inhibitory effect of SKF 104976 on HMGR activity remained unchanged even when the flux of carbon units in the sterol synthesis pathway was reduced by 80%. SKF 104976 did not inhibit HMGR activity under conditions where sterol synthesis was almost completely blocked by lovastatin .
    SKF 104976
  • HY-116034

    Cytochrome P450 Bacterial Fungal Infection
    Arasertaconazole is a potent 14α-lanosterol demethylase inhibitor. Arasertaconazole has antifungal and antibacterial activity .
    Arasertaconazole
  • HY-N14744

    Others Infection
    Lanopylin B2 can inhibit recombinant human lanosterol synthase (EC 5.4.99.7) with an IC50 of 41 μM .
    Lanopylin B2
  • HY-N14740

    Others Infection
    Lanopylin A1 can inhibit recombinant human lanosterol synthase (EC 5.4.99.7) with an IC50 of 15 μM .
    Lanopylin A1
  • HY-162991

    Fluorescent Dye Others
    TCO-PAL-PARP is a PARP PAL probe modified with a trans-cyclooctene group, which can be utilized in live cells .
    TCO-PAL-PARP
  • HY-151440

    Fungal Infection
    Antifungal agent 42 is an antifungal agent. Antifungal agent 42 has an inhibitory effect on lanosterol 14α-demethylase (CYP51) of C.alb.. Antifungal agent 42 inhibits biofilm formation .
    Antifungal agent 42
  • HY-151437

    Fungal Infection
    Antifungal agent 40 is an antifungal agent which extends into the narrow hydrophobic pocket II of C.alb. CYP51. Antifungal agent 40 has an inhibitory effect on lanosterol 14α-demethylase (CYP51). Antifungal agent 40 inhibits biofilm formation .
    Antifungal agent 40
  • HY-155710

    Fungal Infection
    Antifungal agent 68 (compound 10) is an antifungal agent against Candida and Cryptococcus gattii. Antifungal agent 68 inhibits fungal ergosterol biosynthesis, possibly by targeting lanosterol 14α-demethylase (CYP51). There is an interaction between the imidazole ring of antifungal agent 68 and the heme group of CYP51 .
    Antifungal agent 68
  • HY-147919

    Fungal Infection
    Antifungal agent 33 (compound 4e) is a potent antifungal agent. Antifungal agent 33 exhibits remarkable antifungal activity against C. albicans, with a MIC of 16 μg/mL. Antifungal agent 33 shows potent inhibitory activity against Lanosterol 14α-demethylase (CYP51), with an IC50 of 0.19 μg/mL .
    Antifungal agent 33
  • HY-178340

    Cytochrome P450 Fungal Reactive Oxygen Species (ROS) Infection
    Antifungal agent 137 (Compound 4S) is an antifungal agent. Antifungal agent 137 inhibits Phomopsis sp. (PS), with an EC50 of 0.15 μg/mL. Antifungal agent 137 inhibits lanosterol 14α-demethylase (CYP51), with an IC50 of 5.00 μg/mL. Antifungal agent 137 disrupts the morphology of PS mycelia, impairs cell membrane integrity, and induces an increase in intracellular ROS levels, triggering oxidative stress. Antifungal agent 137 can be used for the study of fungal infection .
    Antifungal agent 137
  • HY-B0847S

    Isotope-Labeled Compounds Fungal Reactive Oxygen Species (ROS) Infection
    Propiconazole-d7 is the deuterium labeled Propiconazole. Propiconazole is a broad-spectrum triazole fungicide that inhibits the conversion of lanosterol to ergosterol, leading to fungal cell membrane disruption. Propiconazole inhibits S. cerevisiae, but not rat liver, microsomal cytochrome P450 (IC50s=0.04 and >200 μM, respectively). Propiconazole inhibits the growth of T. deformans and R. stolonifer (ED50s=0.073 and 4.6 μg/mL, respectively). Propiconazole increases production of reactive oxygen species (ROS) .
    Propiconazole-d7
  • HY-B0847S1

    Fungal Reactive Oxygen Species (ROS) Infection
    Propiconazole-d3 (nitrate) is the deuterium labeled Propiconazole nitrate. Propiconazole is a broad-spectrum triazole fungicide that inhibits the conversion of lanosterol to ergosterol, leading to fungal cell membrane disruption. Propiconazole inhibits S. cerevisiae, but not rat liver, microsomal cytochrome P450 (IC50s=0.04 and >200 µM, respectively). Propiconazole inhibits the growth of T. deformans and R. stolonifer (ED50s=0.073 and 4.6 µg/mL, respectively). Propiconazole increases production of reactive oxygen species (ROS).
    Propiconazole-d3 nitrate
  • HY-N14741

    Others Infection
    Lanopylin A2 can inhibit recombinant human lanosterol synthase (EC 5.4.99.7) with an IC50 of 18 μM .
    Lanopylin A2
  • HY-N14743

    Others Infection
    Lanopylin B1 can inhibit recombinant human lanosterol synthase (EC 5.4.99.7) with an IC50 of 33 μM .
    Lanopylin B1
  • HY-105191A

    RS-21607 dihydrochloride

    Heme Oxygenase (HO) Metabolic Disease
    Azalanstat dihydrochloride (RS-21607 dihydrochloride) is an inhibitor of heme oxygenase and lanosterol 14α-demethylase, with inhibitory activity against HO-1 (IC50 = 5.5 µM) and HO-2 (IC50 = 24.5 µM). Azalanstat dihydrochloride reduces the maturation rate of rat oocytes, increases rat oocyte degeneration, and partially inhibits progesterone production in preovulatory follicles of rats .
    Azalanstat dihydrochloride
  • HY-76200C

    (R,R)-UK-109496

    Drug Isomer Others
    (R,R)-Voriconazole ((R,R)-UK-109496) is an enantiomer of Voriconazole (HY-76200). Voriconazole (UK-109496) is a second-generation broad-spectrum triazole antifungal compound that inhibits the biosynthesis of fungal ergosterol. Voriconazole exerts its antifungal activity by inhibiting the 14-α-lanosterol demethylation mediated by fungal cytochrome P450 enzymes. Voriconazole exhibits blood-brain barrier permeability .
    (R,R)-Voriconazole
  • HY-181511

    Cytochrome P450 Fungal Infection
    CYP51-IN-32 is an antifungal agent with an IC50 of 0.331 μM against CYP51 of Candida albicans. CYP51-IN-32 releases hydrogen sulfide (H2S) and inhibits hyphal formation and biofilm development of Candida albicans. CYP51-IN-32 can be formulated into PEG-based nanovesicles. CYP51-IN-32 is applicable to the research of Candida albicans infection .
    CYP51-IN-32
  • HY-W281071

    Fungal Infection
    Antifungal agent 150 is an antifungal agent with activity against phytopathogenic fungi and in planta lesion suppression. Antifungal agent 150 inhibits ergosterol biosynthesis via targeted enzyme interaction. Antifungal agent 150 can be used for the research of plant diseases caused by Rhizoctonia solani, including banded leaf and sheath blight of maize .
    Antifungal agent 150

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: